The Wnt/β-catenin pathway in ovarian cancer: A review

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 772-779

  Arend, Rebecca C ^a   Londoño Joshi, Angelina I ^b   Straughn, J Michael ^a   Buchsbaum, Donald J ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

Ovarian cancer; Wnt; Catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; LGK 974; OMP 18R 5; OMP 54F 28; PRI 724; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VANTICTUMAB; WNT PROTEIN;

APOPTOSIS; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL INTERACTION; CELL MEMBRANE; CELL PROLIFERATION; CHEMOSENSITIZATION; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; METASTASIS; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE; WNT SIGNALING PATHWAY;

EID: 84888298769     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.09.034     Document Type: Review

References (58)

1. B.A. Morton, B.G. Beatty, A.P. Mison, P.M. Wanek, and J.D. Beatty Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice Cancer Res Suppl 50 1990 1008s 1010s
2. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
3. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
4. R.T. Penson, D.S. Dizon, S.A. Cannistra, M.R. Roche, C.N. Krasner, and S.T. Berlin Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors J Clin Oncol 28 2010 154 159
5. A.D. Steg, K.S. Bevis, A.A. Katre, A. Ziebarth, Z.C. Dobbin, and R.D. Alvarez Stem cell pathways contribute to clinical chemoresistance in ovarian cancer Clin Cancer Res 18 2012 869 881
6. F. Ricci, S. Bernasconi, P. Perego, M. Ganzinelli, G. Russo, and F. Bono Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype Cell Cycle 11 2012 1966 1976
7. C. Raimondi, W. Gianni, E. Cortesi, and P. Gazzaniga Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease Curr Cancer Drug Targets 10 2010 496 508
8. L.J. Talbot, S.D. Bhattacharya, and P.C. Kuo Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies Int J Biochem Mol Biol 3 2012 117 136
9. L. Dubeau The cell of origin of ovarian epithelial tumours Lancet Oncol 9 2008 1191 1197
10. A. Boyer, A.K. Goff, and D. Boerboom WNT signaling in ovarian follicle biology and tumorigenesis Trends Endocrinol Metab 21 2010 25 32
11. K. Rask, A. Nilsson, M. Brannstrom, P. Carlsson, P. Hellberg, and P.O. Janson Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta Br J Cancer 89 2003 1298 1304
12. T.A. Gatcliffe, B.J. Monk, K. Planutis, and R.F. Holcombe Wnt signaling in ovarian tumorigenesis Int J Gynecol Cancer 18 2008 954 962
13. N. Takebe, P.J. Harris, R.Q. Warren, and S.P. Ivy Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways Nat Rev Clin Oncol 8 2011 97 106
14. M. Verras, and Z. Sun Roles and regulation of Wnt signaling and beta-catenin in prostate cancer Cancer Lett 237 2006 22 32
15. P. Wend, J.D. Holland, U. Ziebold, and W. Birchmeier Wnt signaling in stem and cancer stem cells Semin Cell Dev Biol 21 2010 855 863
16. S. Vainio, M. Heikkila, A. Kispert, N. Chin, and A.P. McMahon Female development in mammals is regulated by Wnt-4 signalling Nature 397 1999 405 409
17. B.A. Parr, and A.P. McMahon Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a Nature 395 1998 707 710
18. A. Ricken, P. Lochhead, M. Kontogiannea, and R. Farookhi Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs Endocrinology 143 2002 2741 2749
19. M. Saegusa, and I. Okayasu Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation J Pathol 194 2001 59 67
20. R. Wu, Y. Zhai, E.R. Fearon, and K.R. Cho Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas Cancer Res 61 2001 8247 8255
21. Y. Wang, S.M. Hewitt, S. Liu, X. Zhou, H. Zhu, and C. Zhou Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours Br J Cancer 94 2006 686 691
22. E. Karbova, B. Davidson, K. Metodiev, C.G. Trope, and J.M. Nesland Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma Int J Surg Pathol 10 2002 175 180
23. C.M. Lee, H. Shvartsman, M.T. Deavers, S.C. Wang, W. Xia, and R. Schmandt Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma Gynecol Oncol 88 2003 363 368
24. J.M. Gonzalez-Sancho, K.R. Brennan, L.A. Castelo-Soccio, and A.M. Brown Wnt proteins induce dishevelled phosphorylation via an LRP5/6-independent mechanism, irrespective of their ability to stabilize beta-catenin Mol Cell Biol 24 2004 4757 4768
25. P.J. Harris, G. Speranza, and Ullmann C. Dansky Targeting embryonic signaling pathways in cancer therapy Expert Opin Ther Targets 16 2012 131 145
26. A. Kikuchi, H. Yamamoto, and S. Kishida Multiplicity of the interactions of Wnt proteins and their receptors Cell Signal 19 2007 659 671
27. M.V. Barbolina, R.J. Burkhalter, and M.S. Stack Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment Biochem J 437 2011 1 12
28. A.G. Bader, S. Kang, L. Zhao, and P.K. Vogt Oncogenic PI3K deregulates transcription and translation Nat Rev Cancer 5 2005 921 929
29. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
30. L. Badiglian Filho, C.T. Oshima, Lima F. De Oliveira, Costa H. De Oliveira, Damiao R. De Sousa, and T.S. Gomes Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer Oncol Rep 21 2009 313 320
31. R.J. Burkhalter, J. Symowicz, L.G. Hudson, C.J. Gottardi, and M.S. Stack Integrin regulation of beta-catenin signaling in ovarian carcinoma J Biol Chem 286 2011 23467 23475
32. F. Jacob, K. Ukegjini, S. Nixdorf, C.E. Ford, J. Olivier, and R. Caduff Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients PLoS One 7 2012 e31885
33. C.M. Popadiuk, J. Xiong, M.G. Wells, P.G. Andrews, K. Dankwa, and K. Hirasawa Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer Clin Cancer Res 12 2006 2216 2223
34. J.J. Christiansen, and A.K. Rajasekaran Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis Cancer Res 66 2006 8319 8326
35. C.J. Gottardi, E. Wong, and B.M. Gumbiner E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner J Cell Biol 153 2001 1049 1060
36. S. Kumar, A. Kumar, P.P. Shah, S.N. Rai, S.K. Panguluri, and S.S. Kakar MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines J Ovarian Res 4 2011 17
37. E. Al Sawah DM, Y. Xiong, I. Ramirez-Diaz, F. Abbasi, N. Bou Zgheib, and X. Stickles A novel strategy to identify ovarian cancer molecular signaling pathways and drug repurposing candidates Abstract supplement from the Society of Gynecologic Oncology 44th Annual Meeting on Women's Cancer 2013 S7
38. R.J. Flores, Y. Li, A. Yu, J. Shen, P.H. Rao, and S.S. Lau A systems biology approach reveals common metastatic pathways in osteosarcoma BMC Syst Biol 6 2012 50
39. D. Marchion IR-D, Y. Xiong, E. Al Sawah, F. Abbasi, N. Bou Zgheib, and X. Stickles An innovative in silico method to identify agents that target pathways of human cancer chemoresistance Abstract supplement from the Society of Gynecologic Oncology 44th Annual Meeting on Women's Cancer 2013 S151
40. I. Ramirez DM, Y. Xiong, E. Al Sawah, N. Bou Zgheib, B. Boac, and X. Stickles Identifying drug repurposing opportunities to target genes and molecular pathways associated with cancer cell proliferation Abstract supplement from the Society of Gynecologic Oncology 44th Annual Meeting on Women's Cancer 2013 S152
41. U.S. National Institutes of Health. In. http://clinicaltrials.gov.
42. R. Bao, T. Christova, S. Song, S. Angers, X. Yan, and L. Attisano Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells PLoS One 7 2012 e48670
43. S.M. Huang, Y.M. Mishina, S. Liu, A. Cheung, F. Stegmeier, and G.A. Michaud Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 461 2009 614 620
44. J. Waaler, O. Machon, L. Tumova, H. Dinh, V. Korinek, and S.R. Wilson A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice Cancer Res 72 2012 2822 2832
45. T. Osada, M. Chen, X.Y. Yang, I. Spasojevic, J.B. Vandeusen, and D. Hsu Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res 71 2011 4172 4182
46. Y. Jin, Z. Lu, K. Ding, J. Li, X. Du, and C. Chen Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res 70 2010 2516 2527
47. J.X. Pan, K. Ding, and C.Y. Wang Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells Chin J Cancer 31 2012 178 184
48. W. Lu, C. Lin, M.J. Roberts, W.R. Waud, G.A. Piazza, and Y. Li Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway PLoS One 6 2011 e29290
49. Y.T. Yo, Y.W. Lin, Y.C. Wang, C. Balch, R.L. Huang, and M.W. Chan Growth inhibition of ovarian tumor-initiating cells by niclosamide Mol Cancer Ther 11 2012 1703 1712
50. F. Takahashi-Yanaga, and M. Kahn Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16 2010 3153 3162
51. K. Abubaker, A. Latifi, R. Luwor, S. Nazaretian, H. Zhu, and M.A. Quinn Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden Mol Cancer 12 2013 24
52. A. Latifi, K. Abubaker, N. Castrechini, A.C. Ward, C. Liongue, and F. Dobill Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile J Cell Biochem 112 2011 2850 2864
53. L.N. Lili, L.V. Matyunina, L.D. Walker, S.L. Wells, B.B. Benigno, and J.F. McDonald Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis J Ovarian Res 6 2013 49
54. S. Sagae, K. Kobayashi, Y. Nishioka, M. Sugimura, S. Ishioka, and M. Nagata Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas Jpn J Cancer Res 90 1999 510 515
55. J. Palacios, and C. Gamallo Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas Cancer Res 58 1998 1344 1347
56. C. Gamallo, J. Palacios, G. Moreno, J. Calvo de Mora, A. Suarez, and A. Armas beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome Am J Pathol 155 1999 527 536
57. K. Wright, P. Wilson, S. Morland, I. Campbell, M. Walsh, and T. Hurst Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours Int J Cancer 82 1999 625 629
58. G. Moreno-Bueno, C. Gamallo, L. Perez-Gallego, J.C. de Mora, A. Suarez, and J. Palacios Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas Diagn Mol Pathol 10 2001 116 122